Adderall News and Research

RSS

Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.

General public views use of cognitive enhancers as acceptable practice

The general public largely views the use of cognitive enhancers such as Adderall as an acceptable practice when used by adults in the workplace, suggests a new study from Penn Medicine neurologists, which published this week in AJOB Neuroscience.

13 May 2019

ADHD drug raising risk of psychosis

A new study has found that teenagers and youngsters who are treated with amphetamines such as Adderall are at a greater risk of developing psychosis compared to patients who are on other drugs such as Ritalin. The results of the study were published in the latest issue of the New England Journal of Medicine.

21 Mar 2019

ADHD patients have increased risk of developing Parkinson's and other similar diseases

While about 11 percent of children (4-17 years old) nationwide have been diagnosed with attention-deficit hyperactivity disorder, the long-term health effects of having ADHD and of common ADHD medications remains understudied.

12 Sep 2018

ADHD medications may fail to improve cognition in healthy college students, study shows

Contrary to popular belief across college campuses, attention deficit hyperactivity disorder medications may fail to improve cognition in healthy students and actually can impair functioning, according to a study by researchers at the University of Rhode Island and Brown University.

20 Jul 2018

Graphic: Opioid painkiller is top prescription in 11 states

Americans fill about 4.5 billion prescriptions each year, at a cost of more than $323 billion. But what are we actually buying? In 11 states, the top prescriptions are opioid pain pills that are mixtures of acetaminophen and hydrocodone (brand names Vicodin and Norco), according to new data from GoodRx, an online prescription cost service.

22 Mar 2018

NIH awards $2 million grant to test effectiveness of nonmedication ADHD treatments

Florida State University researchers are seeing promising results from "video games" they created as a potential new option to treat Attention-Deficit/Hyperactivity Disorder without medication.

24 Jan 2018

Chapman University research explores substance abuse among transgender adolescents in California

Chapman University has published research on substance abuse among transgender students in California. The research looked at students in middle and high schools in nearly every school district in California.

17 Aug 2017

ADHD medicines linked to lower risk for substance use problems in adolescents, adults

The use of medication to treat attention deficit hyperactivity disorder is linked to significantly lower risk for substance use problems in adolescents and adults with ADHD, according to a study led by researchers at Indiana University.

12 Jul 2017

UB researchers explore potential side effects of stimulant drug on people without ADHD

New research from the University at Buffalo Research Institute on Addictions that explored the potential side effects of the stimulant drug Ritalin on those without ADHD showed changes in brain chemistry associated with risk-taking behavior, sleep disruption and other undesirable effects.

16 May 2017

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.

12 Jul 2016

U-M study compares early-use and longer-duration stimulant medication with nonstimulant therapy for ADHD

Youth who take Ritalin, Adderall or other stimulant medications for ADHD over an extended period of time early in life are no more at risk for substance abuse in later adolescence than teens without ADHD, according to a University of Michigan study.

9 Jun 2016

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States.

16 May 2016

Misuse of Adderall drug rising among young adults, research suggests

While the number of prescriptions for the stimulant Adderall has remained unchanged among young adults, misuse and emergency room visits related to the drug have risen dramatically in this group, new Johns Hopkins Bloomberg School of Public Health research suggests.

17 Feb 2016

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.

25 Jan 2016

Drug use remains stable among teens, MTF survey shows

The 2015 Monitoring the Future survey (MTF) shows decreasing use of a number of substances, including cigarettes, alcohol, prescription opioid pain relievers, and synthetic cannabinoids ("synthetic marijuana"). Other drug use remains stable, including marijuana, with continued high rates of daily use reported among 12th graders, and ongoing declines in perception of its harms.

17 Dec 2015

Stimulant medications for ADHD cause sleep problems among children

Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) cause sleep problems among the children who take them, a new study from the University of Nebraska-Lincoln concludes.

23 Nov 2015

Researchers explain why ADHD continues to affect many adults

Attention-deficit/hyperactivity disorder is growing up. Stephen Hinshaw and Katherine Ellison authors of the newly published book, ADHD: What Everyone Needs to Know, confirm that adults -- and particularly women -- are reporting to clinics in record numbers, becoming the fastest-growing part of the population receiving diagnoses and prescriptions for stimulant medications.

5 Nov 2015

Misuse of prescription drugs common among U.S. college students

Seven out of 10 college students say it is somewhat or very easy to obtain controlled stimulants without a prescription, according to a new survey conducted on eight U.S. campuses.

19 Oct 2015

Shire enters into agreement with Sanquin for CINRYZE

Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.

25 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015